ABVC — ABVC BioPharma, Inc.
ABVC BioPharma, Inc. is a clinical-stage biopharmaceutical company focused on creating novel drugs and medical devices to address critical, underserved healthcare requirements across the United States. The company's pipeline includes several key candidates: ABV-1501, currently undergoing Phase I/II clinical trials, is being developed as a combination treatment for triple-negative breast cancer. ABV-1504 has successfully completed Phase II clinical trials for major depressive disorders. ABV-1505 is progressing through Phase II clinical studies for attention deficit hyperactivity disorder (ADHD). ABV-1703 has concluded its Phase I clinical trials for the treatment of pancreatic cancer. ABV-1702 has also finished Phase I clinical investigations for myelodysplastic syndromes. ABV-1601 is in Phase I/II clinical trials, aimed at alleviating depression in individuals with cancer. ABV-1701 Vitargus is in development to treat conditions such as retinal detachment or vitreous hemorrhage. ABVC BioPharma maintains strategic alliances, including a co-development arrangement with Rgene Corporation, alongside collaborative agreements with BioHopeKing Corporation and BioFirst Corporation. The company's headquarters are located in Fremont, California, and it operates as a subsidiary of YuanGene Corporation.
Company profile
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
- Exchange: NASDAQ Capital Market
- Employees: 16
- Website: https://www.abvcpharma.com
Latest SEC filings for ABVC
- 10-Q — 2026-05-18
- NT 10-Q — 2026-05-15
- POS AM — 2026-03-27
- 8-K — 2026-03-27
- 10-Q/A — 2026-03-03
- 10-K — 2026-03-03
- 8-K — 2026-03-03
- 8-K/A — 2026-01-16
- 424B4 — 2025-11-14
- 424B4 — 2025-11-14
Educational tool only — not investment advice.